Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 9/20 | 0.41 |
| ▸ | CES1 | P23141 | 9/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7965444 | 0.87 | CES2 (0.36) | CES2CES1ERN1SRCHCAR1 | |
| SCHEMBL6029780 | 0.81 | HTT (0.41) | CYP2C19HTTRAB9A | |
| SCHEMBL7950440 | 0.79 | GRM2 (0.36) | CES2CES1SRCHCAR1 | |
| SCHEMBL16996749 | 0.79 | CES2 (0.40) | CES2CES1ERN1HCAR1HTT | |
| SCHEMBL1462346 | 0.77 | PTGS2 (0.44) | ALDH1A1CYP2C19HTTRAB9A | |
| SCHEMBL5250437 | 0.76 | CES2 (0.50) | CES2CES1SRCALDH1A1SMN1; SMN2 | |
| SCHEMBL6452270 | 0.76 | CES2 (0.53) | CES2CES1ERN1SRCHCAR1 | |
| SCHEMBL14746583 | 0.76 | CYP3A4 (0.40) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL4074821 | 0.75 | MAPT (0.39) | — | |
| SCHEMBL3686370 | 0.74 | MAPK1 (0.36) | CES2CES1ERN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903436-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | UNIV PENNSYLVANIA (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| EP-2903436-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
| US-7501423-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7396835-B2 | Process for the preparation of tubulin inhibitors | WYETH (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1891052-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | Wyeth (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1343787-B1 | 6-PHENYL-PYRAZOLOPYRIMIDINES | BASF AG (DE) | 2004-11-10 | — | — | EP | disclosed |
| EP-1431299-A1 | IMIDAZO(1,2-a)PYRIMIDINES AND FUNGICIDE COMPOSITIONS CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004046149-A1 | 2-MERCAPTO-SUBSTITUTED TRIAZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, THE USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI, AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-03 | — | — | WO | disclosed |
| US-6730680-B2 | FUNGICIDES FOR CONTROLLING PHYTOPATHOGENIC FUNGI; AGRICULTURE, PLANT DISEASES | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-04 | — | — | US | disclosed |
| EP-1343787-A1 | 6-PHENYL-PYRAZOLOPYRIMIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20030158190-A1 | 6-phenyl-pyrazolopyrimidines | PEES KLAUS JUERGEN (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6552026-B2 | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-22 | — | — | US | disclosed |
| WO-2002048151-A1 | 6-PHENYL-PYRAZOLOPYRIMIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | disclosed |
| US-20020049318-A1 | 6-phenyl-pyrazolopyrimidines | BASF CORPORATION (US) | 2002-04-25 | — | — | US | disclosed |
| US-6156925-A | Process for the preparation of halogenated phenylmaloates | AMERICAN CYANAMID COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | CES2 3163/4885CES1 4382/4885ERN1 2544/4885 |
| US-20030158190-A1 | 6-phenyl-pyrazolopyrimidines | CBR1, CBR3, CNPY2 | CES2 3526/4885CES1 3216/4885ERN1 494/4885 |
| US-20020049318-A1 | 6-phenyl-pyrazolopyrimidines | CBR1, CBR3, CNPY2 | CES2 3526/4885CES1 3216/4885ERN1 494/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | CES2 4112/4885CES1 4801/4885ERN1 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.